X4 Pharmaceuticals, Inc. (XFOR) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 2.71M | 2.57M | 1.76M | 1.97M | 28.81M | 1.43M | 560K | 563K | 0 | 0 | 0 | 0 |
| Revenue Growth % | -90.6% | 79.08% | 215.18% | 250.44% | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 598K | 387K | 374K | 494K | 5M | 302K | 307K | 462K | 62K | 62K | 502K | 516K |
| COGS % of Revenue | 22.08% | 15.07% | 21.19% | 25.04% | 17.37% | 21.06% | 54.82% | 82.06% | - | - | - | - |
| Gross Profit | 2.11M | 2.18M | 1.39M | 1.48M | 23.8M | 1.13M | 253K | 101K | -62K | -62K | -502K | -516K |
| Gross Margin % | 77.92% | 84.93% | 78.81% | 74.96% | 82.63% | 78.94% | 45.18% | 17.94% | - | - | - | - |
| Gross Profit Growth % | -91.14% | 92.67% | 449.8% | 1364.36% | 38490.32% | 1925.81% | 150.4% | 119.57% | 87.89% | 87.62% | -1.62% | -3.2% |
| Operating Expenses | 22.42M | 25.88M | 28.9M | 27.71M | 33.24M | 36.85M | 34.75M | 34M | 37.23M | 25.14M | 26.71M | 25.29M |
| OpEx % of Revenue | 827.77% | 1007.79% | 1637.39% | 1404.51% | 115.41% | 2569.53% | 6205.89% | 6038.72% | - | - | - | - |
| Selling, General & Admin | 6.97M | 7.38M | 11.59M | 9.53M | 15.02M | 15.14M | 15.66M | 13.28M | 17.43M | 9.93M | 8.13M | 10.2M |
| SG&A % of Revenue | 257.24% | 287.46% | 656.43% | 482.87% | 52.14% | 1056.14% | 2796.43% | 2358.44% | - | - | - | - |
| Research & Development | 15.45M | 18.5M | 17.31M | 18.18M | 18.22M | 21.7M | 19.09M | 20.72M | 19.79M | 15.21M | 18.58M | 15.09M |
| R&D % of Revenue | 570.53% | 720.33% | 980.96% | 921.64% | 63.26% | 1513.39% | 3409.46% | 3680.28% | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -20.31M | -23.7M | -27.51M | -26.23M | -9.44M | -35.72M | -34.5M | -33.9M | -37.29M | -25.2M | -27.21M | -25.8M |
| Operating Margin % | -749.85% | -922.86% | -1558.58% | -1329.55% | -32.78% | -2490.59% | -6160.71% | -6020.78% | - | - | - | - |
| Operating Income Growth % | -115.04% | 33.64% | 20.26% | 22.61% | 74.68% | -41.73% | -26.77% | -31.36% | -27.25% | 1.48% | -35.03% | -25.45% |
| EBITDA | -20.07M | -23.48M | -27.29M | -25.86M | -8.95M | -35.44M | -34.22M | -33.7M | -37.23M | -25.14M | -26.71M | -25.29M |
| EBITDA Margin % | -741.14% | -914.17% | -1545.95% | -1310.9% | -31.08% | -2471.55% | -6110.71% | -5986.32% | - | - | - | - |
| EBITDA Growth % | -124.15% | 33.76% | 20.26% | 23.26% | 75.95% | -41% | -28.11% | -33.27% | -29.3% | -0.24% | -35.87% | -26% |
| D&A (Non-Cash Add-back) | 236K | 223K | 223K | 368K | 489K | 273K | 280K | 194K | 62K | 62K | 502K | 516K |
| EBIT | -20.31M | -23.7M | -27.51M | -26.23M | -9.44M | -37.26M | -34.5M | -33.9M | -37.29M | -25.2M | -27.21M | -25.8M |
| Net Interest Income | -29K | -201K | -1.36M | -1.57M | -1.18M | -1.04M | -543K | -611K | -808K | -441K | -246K | -234K |
| Interest Income | 2.1M | 1.99M | 901K | 665K | 1.02M | 1.27M | 1.87M | 1.56M | 1.07M | 1.45M | 1.39M | 914K |
| Interest Expense | 2.13M | 2.19M | 2.26M | 2.23M | 2.2M | 2.3M | 2.41M | 2.18M | 1.87M | 1.89M | 1.63M | 1.15M |
| Other Income/Expense | 65K | -226K | -2.34M | 528K | 9.76M | -3.85M | -2.18M | 124.75M | -14.46M | 6.1M | 24.93M | -29.89M |
| Pretax Income | -20.24M | -23.93M | -29.84M | -25.7M | 316K | -39.56M | -36.68M | 90.85M | -51.75M | -19.1M | -2.28M | -55.7M |
| Pretax Margin % | -747.45% | -931.66% | -1690.93% | -1302.79% | 1.1% | -2758.93% | -6550.18% | 16136.94% | - | - | - | - |
| Income Tax | 0 | 0 | -30K | 37K | 34K | 258K | 15K | 18K | 19K | 33K | 26K | 15K |
| Effective Tax Rate % | 0% | 0% | 0.1% | -0.14% | 10.76% | -0.65% | -0.04% | 0.02% | -0.04% | -0.17% | -1.14% | -0.03% |
| Net Income | -20.24M | -23.93M | -29.82M | -25.74M | 282K | -39.82M | -36.7M | 90.83M | -51.77M | -19.13M | -2.31M | -55.71M |
| Net Margin % | -747.45% | -931.66% | -1689.24% | -1304.66% | 0.98% | -2776.92% | -6552.86% | 16133.75% | - | - | - | - |
| Net Income Growth % | -7277.66% | 39.92% | 18.75% | -128.34% | 100.54% | -108.16% | -1492.02% | 263.04% | -115.51% | 34.27% | 89.32% | -162.64% |
| Net Income (Continuing) | -20.24M | -23.93M | -29.82M | -25.74M | 282K | -39.82M | -36.7M | 90.83M | -51.77M | -19.13M | -2.31M | -55.71M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.16 | -0.22 | -0.69 | -3.47 | 0.04 | -6.00 | -5.48 | 13.57 | -7.77 | -2.89 | -0.35 | -9.91 |
| EPS Growth % | -500% | 96.33% | 87.41% | -125.57% | 100.51% | -107.61% | -1465.71% | 236.93% | -57.29% | 66.63% | 95.56% | 44.82% |
| EPS (Basic) | -0.16 | -0.22 | -0.69 | -3.47 | 0.04 | -6.00 | -5.48 | 13.60 | -7.77 | -2.89 | -0.35 | -9.91 |
| Diluted Shares Outstanding | 126.29M | 110.56M | 43.27M | 7.41M | 6.87M | 6.76M | 6.7M | 6.69M | 6.67M | 6.63M | 6.57M | 5.62M |
| Basic Shares Outstanding | 126.29M | 110.56M | 43.27M | 7.41M | 6.84M | 6.76M | 6.7M | 6.68M | 6.67M | 6.63M | 6.57M | 5.62M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |